Related Experiment Video
Updated: Jun 13, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Update on developmental therapeutics for acute lymphoblastic leukemia
1Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Boulevard, Room 7025, Bethesda, MD 20892, USA. smithm@ctep.nci.nih.gov
Current Hematologic Malignancy Reports
|April 29, 2010
Summary
New drug development for acute lymphoblastic leukemia (ALL) is accelerating. Advances in preclinical models, molecular understanding, and targeted therapies promise more effective treatments for ALL in the next decade.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Acute lymphoblastic leukemia (ALL) drug development is advancing rapidly.
- Understanding the molecular and genomic changes in B-cell and T-cell ALL is crucial.
- Preclinical models for ALL are becoming more representative.
Purpose of the Study:
- To review current trends and novel agents in acute lymphoblastic leukemia (ALL) drug development.
- To highlight molecularly targeted therapies for ALL.
- To discuss the potential of new agents in the coming decade.
Main Methods:
- Review of recent advancements in ALL research.
- Analysis of molecular targets and genomic alterations in ALL.
- Discussion of novel therapeutic agents and their mechanisms of action.
Main Results:
- Several trends are converging to accelerate ALL drug development.
- Novel agents targeting specific molecular pathways show promise.
- Improved preclinical models aid in agent prioritization.
Conclusions:
- The next decade is poised for significant breakthroughs in ALL treatment.
- Targeted therapies represent a promising frontier for ALL drug development.
- Continued research into molecular targets will drive therapeutic innovation.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...